Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
8 evidence topics · 10 sources
Bladder cancer new cases in the United States, 2026 estimate
Bladder cancer incidence rate, lifetime risk, and age at diagnosis
Share of bladder cancer diagnosed as non-muscle-invasive disease
Population funnel from bladder cancer to BCG-unresponsive high-risk NMIBC, SEER and SEER-Medicare inputs
Population funnel assumptions in the ICER review: NMIBC stage mix and BCG non-response
BCG-unresponsive share among recurrences after BCG, US electronic health record and claims cohort
“The study included 26 876 patients with NMIBC (median [IQR] age at BCG initiation, 73 [65-77] years; 79.5% male), including 9639 patients with carcinoma in situ” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 5271 patients with carcinoma in situ–containing tumors and sufficient follow-up, 3134 (59.3%) experienced recurrence within 24 months, of whom 2604 (83.1%) were BCG exposed and 530 (16.9%) were BCG unresponsive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCG-unresponsive share among classifiable BCG-treated high-grade NMIBC, single-center cohort
“We conducted a retrospective cohort study for adults with histologically confirmed high-grade NMIBC treated with intravesical BCG at Moffitt Cancer Center between 1988 and 2024.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 1076 NMIBC patients treated with BCG, 470 were classifiable: 245 (52.1%) were BCG-E, of whom 173 (70.6%) were resistant and 72 (29.4%) experienced delayed relapse, and 225 (47.9%) were BCG-UR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote